Cambridge Healthtech Institute’s Inaugural
T Cell Engagers
Expanding Therapeutic Window and Widening Indication Space
17 November 2026
The T Cell Engagers conference will explore how to expand the therapeutic window of TCEs while widening indication space across oncology and immune-mediated disease. Sessions will address dual and triple targeting, conditional and tumour-selective CD3 engagement, and innovative safety switches that reshape tolerability. The meeting also looks beyond conventional CD3-based engagers to NK, γδ, MAIT, and myeloid cell engagers, as well as applications in autoimmunity and infection.
Coverage will include, but is not limited to:
IMPROVING TCE EFFICACY & WIDENING INDICATION SPACE
- Dual and triple targeting to combat tumour heterogeneity and antigen escape
- Combining TCEs with checkpoint inhibitors, costimulatory agonists (CD28, 4-1BB, Cd2) and cytokines to turn cold tumours hot
- Enabling epitope spreading and local production of TCEs via CAR-T cells oncolytic viruses or cancer vaccines
IMPROVING TCE SAFETY WITH CONDITIONAL APPROACHES—WIDENING THE THERAPEUTIC WINDOW
- pH-sensitive antibody platforms for tumour-selective CD3 engagement
- Protease-mediated unmasking of TCE activity
- ATP-activatable antibodies for TME-selective TCE engagement
- Engineering CD3 binding arm for improved selectivity and tolerability
- Targeting selective T cell populations CD8-only engagers, MAIT cell redirectors, CMV-reactive T cell targeting, and γδ T cell engagers
- Increasing target space by conditional approaches – pMHC targeting
- Logic-Gated and Co-Stimulated TCE Platform: From Conditional Activation to IND Readiness
NEXT-GENERATION IMMUNE CELL ENGAGERS: BEYOND TRADITIONAL T CELLS
- Beyond CD3-based TCEs: CD8-targeted TITAN formats, TCR-based engagers, TriKEs
- NK, γδ and MAIT cell engagers
- Macrophage and myeloid cell engagers (e.g., CD47, other myeloid checkpoints) and complement engagers (BiCEs)
- Targeting antigens such as B7 H3 and disease specific B cell receptors with bispecific engagers
- Novel TCE formats beyond IgG: DARPin-based, nanobody-based, and RNA-encoded TCEs
The deadline for priority consideration is 26 March 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: